In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteria

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 12, 2010, Pages 2590-2597

  Dubuisson, Tia ^a   Bogatcheva, Elena ^a   Krishnan, Manju Y ^b   Collins, Michael T ^b   Einck, Leo ^a   Nacy, Carol A ^a   Reddy, Venkata M ^a  

^a SEQUELLA INC   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Mycobacterium abscessus; Mycobacterium avium complex; Mycobacterium avium paratuberculosis; SQ641

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; ETHAMBUTOL; RKS 2244; SQ 641; SQ 922; SQ 997; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG POTENTIATION; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM PARATUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM ULCERANS; NONHUMAN;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; COLONY COUNT, MICROBIAL; DRUG SYNERGISM; ETHAMBUTOL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM SUBSP. PARATUBERCULOSIS; MYCOBACTERIUM INFECTIONS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM ULCERANS;

EID: 78149482837     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq372     Document Type: Article

References (26)

1. Bugg TD, Lloyd AJ, Roper DI. Phospho-MurNAc-pentapeptide translocase (MraY) as a target for antibacterial agents and antibacterial proteins. Infect Disord Drug Targets 2006; 6: 85-106.
2. Kimura K, Bugg TD. Recent advances in antimicrobial nucleoside antibiotics targeting cell wall biosynthesis. Nat Prod Rep 2003; 20:252-73.
3. O'Brien R. The treatment of tuberculosis. In: Reichman LB, Hershfield ES, eds. Tuberculosis: A Comprehensive International Approach. New York: Marcel Dekker, 1993; 207-40.
4. Yamaguchi H, Sato S, Yoshida S et al. Capuramycin, a new nucleoside antibiotic. Taxonomy, fermentation, isolation and characterization. J Antibiot 1986; 39: 1047-53.
5. Muramatsu Y, Muramatsu A, Ohnuki T et al. Studies on novel bacterial translocase I inhibitors, A-5300359s. I. Taxonomy, fermentation, isolation, physico-chemical properties and structure elucidation of A-500359 A, C, D and G. J Antibiot 2003; 56: 243-52.
6. Hotoda H, Furukawa M, Daigo M et al. Synthesis and antimycobacterial activity of capuramycin analogues. Part 1: substitution of the azepan-2-one moiety of capuramycin. Bioorg Med Chem Lett 2003; 13: 2829-32.
7. Hotoda H, Daigo M, Furukawa M et al. Synthesis and antimycobacterial activity of capuramycin analogues. Part 2: acylated derivatives of capuramycin-related compounds. Bioorg Med Chem Lett 2003; 13: 2833-36.
8. Hotoda H, Kanenko M, Inukai M et al. Antibacterial Compound.US Patent #7157442B2. USA: Sankyo Company, Limited (Tokyo, JP), 2007.
9. Koga T, Fukuoka T, Doi N et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. J Antimicrob Chemother 2004; 54: 755-60.
10. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
11. Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu Rev Microbiol 2004; 58: 329-63.
12. Pierce ES. Where are all the Mycobacterium avium subspecies paratuberculosis in patients with Crohn's disease? PLoS Path 2009; 5:1-11.
13. Uzoigwe JC, Khaitsa ML, Gibbs PS. Epidemiological evidence for Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Epidemiol Infect 2007; 135: 1057-68.
14. De Groote MA, Huitt G. Infections due to rapidly growing mycobacteria. Clin Infect Dis 2006; 42: 1756-63.
15. Johnson PDR, Stinear T, Small PLC et al. Buruli ulcer (M. ulcerans): new insights and new hope for disease control. PLoS Medicine 2005; 2: 282-86.
16. Reddy VM, Einck L, Nacy CA. In vitro antimycobacterial activities of capuramycin analogues. Antimicrob Agents Chemother 2008; 52: 719-21.
17. Wallace RJ, Nash DR, Steel LC. Susceptibility testing of slowly growing mycobacteria by a microdilution MIC method with 7H9 broth. J Clin Microbiol 1986; 24: 976-81.
18. Krishnan MY, Manning EJB, Collins MT. Comparison of three methods for susceptibility testing of Mycobacterium avium subsp. paratuberculosis to 11 antimicrobial drugs. J Antimicrob Chemother 2009; 64: 310-16.
19. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1.
20. Reddy VM, Luna-Herrera J, Gangadharam PRJ. Pathobiological significance of colony morphology in Mycobacterium avium complex. Microbial Pathog 1996; 21: 97-109.
21. Heifets LB. Antituberculosis drugs: antimicrobial activity in vitro. In: Heifets LB, ed. Drug Susceptibility in the Chemotherapy of Mycobacterial Infections. Boca Raton: CRC Press, 1991; 13-57.
22. Chadwick EG, Shulman ST, Yogev R. Correlation of antibiotic synergy in vitro and in vivo: use of an animal model of neutropenic gram-negative sepsis. J Infect Dis 1986; 154: 670-5.
23. Moody JA, Fasching CE, Petterson LR et al. Ceftazidime and amikacin alone and in combination against Pseudomonas aeruginosa and Enterobacteriaceae. Diagn Microbiol Infect Dis 1987; 6: 59-67.
24. Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. Clin Infect Dis 2003; 36: 615-21.
25. Jacqueline C, Navas D, Batard E et al. In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005; 49: 45-51.
26. Nikonenko BV, Reddy VM, Protopopova M et al. Activity of SQ641, a capuramycin analog, in a murine model of tuberculosis. Antimicrob Agents Chemother 2010; 53: 3138-9.